Status In progress
Process STA
ID number 1209

Provisional Schedule

Expected publication 15 August 2018

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Merck Sharp & Dohme
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Fight Bladder Cancer
Professional groups British Uro Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies Accord Healthcare/Actavis UK (carboplatin, gemcitabine) (CAU not returned, not participating)
  Eli Lilly (gemcitabine)
  Hospira UK (carboplatin, gemcitabine) (CAU not returned, not participating)
  Roche (atezolizumab – subject to ongoing NICE appraisal)
  Sun Pharmaceuticals UK (carboplatin, gemcitabine) (CAU not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
08 March 2018 Committee meeting: 1
28 September 2017 In progress, In progress
26 September 2017 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance